Cover Image
市場調查報告書

EpiCast Report:老年性黃斑部病變的流行病學預測

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 312373
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:老年性黃斑部病變的流行病學預測 EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
出版日期: 2014年09月10日 內容資訊: 英文 38 Pages
簡介

老年性黃斑部病變(AMD),是由於在視網膜擔任中心視野之黃斑逐步劣化所引起,進行性的眼科疾病。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的老年性黃斑部病變(AMD)的患病數量,預計從2013年的55,770,401件,今後10年達到66,069,370件,增加18.5%。

本報告提供全球主要7個國家的老年性黃斑部病變(AMD)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • 主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
  • AMD的流行病學預測
    • AMD的整體患病數量
    • AMD的整體患病數量:各年齡
    • AMD的整體患病數量:性別
    • AMD的整體得病率:年齡標準化
    • AMD的整體患病數量:各階段
    • AMD後期的整體患病數量:各子類型
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER066-14

Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in developed countries. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified into dry AMD (geographic atrophy) and wet AMD (neovascular).

GlobalData epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.

GlobalData's epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD; GlobalData epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.

Scope

  • The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for AMD (2013-2023)
    • 3.5.1. Total Prevalent Cases of AMD
    • 3.5.2. Age-Specific Total Prevalent Cases of AMD
    • 3.5.3. Sex-Specific Total Prevalent Cases of AMD
    • 3.5.4. Age-Standardized Total Prevalence of AMD
    • 3.5.5. Total Prevalent Cases of AMD by Stage
    • 3.5.6. Total Prevalent Cases of Late AMD by Subtype
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for AMD
  • Table 2: Diagnostic Criteria for AMD
  • Table 3: 7MM, Sources of AMD Prevalence Data
  • Table 4: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Table 5: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013
  • Table 6: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N (Row %), 2013
  • Table 7: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N (Row %), 2013
  • Table 8: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N (Row %), 2013

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ≥50 Years, by Sex, 2013
  • Figure 5: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N, 2013
  • Figure 6: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N, 2013
Back to Top